Fulvestrant intraductal - Atossa GeneticsAlternative Names: Fulvestrant - Atossa Genetics
Latest Information Update: 08 Mar 2016
At a glance
- Originator Atossa Genetics
- Class Antineoplastics; Estradiol congeners; Estrenes
- Mechanism of Action Estrogen receptor antagonists; Selective estrogen receptor degraders
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer